Intervention prospective monocentric one arm study on the use of neoadjuvant radiotherapy with simultaneous integrated boost (Simultaneous Integrated Boost, SIB) in patients with STS with indication for preoperative radiotherapy. The treatment will be administered in 25 daily fractions (Monday-Friday) at the disease site to include the region of suspected micrometastatic spread (Clinical Target Volume 1, CTV1) at a dose of 50 Gy (2Gy
/ fraction) with SIB intensification on volume reduced corresponding to the interface sites between the tumor and the vascular / nerve axes (Clinical Target Volume 2, CTV2) at a dose of 60 Gy (2.4 Gy / fraction). The association with neoadjuvant chemotherapy based on anthracyclines is allowed.
Patients aged ≥ 18 years
Confirmed histological diagnosis of soft tissue sarcoma
Candidate for conservative surgery
Performance status ≤ 1 according to WHO (or ≥ 70 according to KPS) before starting the treatment in the office.
Previous radiotherapy at the same site
Candidate for Surgical Amputation
Patients with comorbidities for collagen diseases
Psychiatric disorders that may preclude obtaining the informed consent